Latest Stories for GlycoMimetics, Inc.dlvr.it Promoted Storieshttps://static.dlvr.it/images/d.pnghttps://static.dlvr.it/images/favicon.icotag:news.dlvr.it,2015-04-13:/organization/651082015-04-13T06:49:11-07:00tag:news.dlvr.it,2015-04-07:3731852015-04-07T04:00:52-07:00
– GlycoMimetics to receive $20 million milestone payment upon dosing
of first patient in trial –
]]>tag:news.dlvr.it,2015-03-19:3695192015-03-19T06:30:16-07:00]]>tag:news.dlvr.it,2015-03-16:3638742015-03-16T13:30:34-07:00
Year-End Cash and Cash Equivalents of $55.2 million
]]>tag:news.dlvr.it,2015-03-03:3473362015-03-03T06:06:10-08:00
- Data underscores potential to provide meaningful clinical
benefits and pharmacoeconomic impacts for patients in vaso-occlusive
crisis -
]]>tag:news.dlvr.it,2015-02-26:3515232015-02-26T06:04:47-08:00]]>tag:news.dlvr.it,2015-02-03:3410942015-02-03T06:05:48-08:00]]>tag:news.dlvr.it,2014-12-09:3306182014-12-09T06:09:01-08:00
Preclinical Data Shared Through Four Oral Presentations and One
Poster Focus on the Potential Role of GMI-1271 in Treating Blood
Cancers and Coagulation Disorders
Biomarker Data from Phase 2 Study of Rivipansel Also Displayed via
Poster Session at ASH Meeting
]]>tag:news.dlvr.it,2014-12-04:3165292014-12-04T06:04:07-08:00
- National Heart Lung and Blood Institute grant is funding
University of Michigan Phase 1 trial
]]>tag:news.dlvr.it,2014-11-17:3187262014-11-17T13:00:13-08:00
- E-selectin antagonist GMI-1271 to advance to chemo-combination
study in AML -
]]>tag:news.dlvr.it,2014-11-12:3299782014-11-12T06:06:37-08:00]]>tag:news.dlvr.it,2014-11-06:3316042014-11-06T06:33:13-08:00
Preclinical data on GMI-1271 in four oral presentations and one
poster focus on blood cancers and coagulation disorders
New data for rivipansel, sickle cell investigational drug
candidate, show effects on biomarkers
]]>tag:news.dlvr.it,2014-10-31:3161892014-10-31T06:15:07-07:00]]>tag:news.dlvr.it,2014-08-08:2899912014-08-08T07:39:10-07:00]]>tag:news.dlvr.it,2014-07-31:2873332014-07-31T13:00:38-07:00]]>tag:news.dlvr.it,2014-07-10:2805782014-07-10T06:08:46-07:00
- Dr. Goldberg Brings Perspective as Medical Oncologist and
Hematologist and Extensive Biopharmaceutical Regulatory Experience to
GlycoMimetics Board -
]]>
– GlycoMimetics to receive $20 million milestone payment upon dosing
of first patient in trial –
]]>
]]>
Year-End Cash and Cash Equivalents of $55.2 million
]]>
- Data underscores potential to provide meaningful clinical
benefits and pharmacoeconomic impacts for patients in vaso-occlusive
crisis -
]]>
]]>
]]>
Preclinical Data Shared Through Four Oral Presentations and One
Poster Focus on the Potential Role of GMI-1271 in Treating Blood
Cancers and Coagulation Disorders
Biomarker Data from Phase 2 Study of Rivipansel Also Displayed via
Poster Session at ASH Meeting
]]>
- National Heart Lung and Blood Institute grant is funding
University of Michigan Phase 1 trial
]]>
- E-selectin antagonist GMI-1271 to advance to chemo-combination
study in AML -
]]>
]]>
Preclinical data on GMI-1271 in four oral presentations and one
poster focus on blood cancers and coagulation disorders
New data for rivipansel, sickle cell investigational drug
candidate, show effects on biomarkers
]]>
]]>
]]>
]]>
- Dr. Goldberg Brings Perspective as Medical Oncologist and
Hematologist and Extensive Biopharmaceutical Regulatory Experience to
GlycoMimetics Board -
]]>